You are here: Industry Insights > cancer drug

News List

MacroGenics halts trials of cancer drug after FDA partial hold fiercebiotech
December 28, 2018
Potential liver-related side effects have led to the FDA placing a partial clinical hold on a MacroGenics-developed bispecific antibody for cancer.....
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
December 24, 2018
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments......
AZ’s cancer drug fails again, Roche’s rival gets new use pharmaphorum
December 10, 2018
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication.
Johnson & Johnson pays $300 million upfront under deal to develop argenx's cancer drug cusatuzumab firstwordpharma
December 03, 2018
Johnson & Johnson's Janssen Pharmaceutical unit entered an agreement potentially worth up to $1.6 billion to develop and market argenx's cusatuzumab in a number of cancers, including haematological malignancies, the companies announced Monday.
Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer endpts
November 27, 2018
The FDA has hustled up a quick OK for larotrectinib, offering their stamp of approval for a site-agnostic cancer drug from Loxo Oncology and their partners at Bayer...
Roche-AbbVie cancer drug gets accelerated FDA approval expressbpd
November 24, 2018
Roche Holding said its cancer drug, Venclexta, received accelerated approval from the US Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.
Roche-AbbVie cancer drug gets accelerated FDA approval expressbpd
November 24, 2018
Roche Holding said its cancer drug, Venclexta, received accelerated approval from the US Food and Drug Administration as part of a combination treatment for newly diagnosed patients with a form of leukemia.
Novartis to acquire US cancer drug developer Endocyte for $2.1bn pharmaceutical-technology
October 22, 2018
The completion of the acquisition is conditional on customary closing conditions, including shareholder approval and regulatory approvals.
Pace of cancer drug reimbursement varies wildly across Europe pharmaceutical-technology
October 22, 2018
Researchers have found that some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions about reimbursing cancer drugs following European Medicines Agency (EMA) approval.
MEI Pharma, BeiGene to co-develop cancer drug biospectrum
October 15, 2018
Under the terms of the clinical collaboration agreement, MEI will amend its ongoing Phase 1b trial to include evaluation of ME-401 in combination with zanubrutinib in patients with B-cell malignancies

Previous page 1 2 3 4 5 6 Next page